An expert panel from India’s top drug regulator on Saturday recommended restricted emergency approval for Covaxin, Bharat Biotech’s Covid-19 candidate vaccine currently being tested in the country. The panel of experts now recommended a restricted authorization for two candidate vaccines in as many days; on Friday, it recommended similar approval …
Read More »Expert Panel Recommends Granting Approval for Emergency Restricted Use of Covaxin from Bharat Biotech
An expert panel from India’s central drug authority on Saturday recommended granting permission for the restricted use of the indigenous COVID-19 vaccine developed by Bharat Biotech Covaxin in an emergency situation, especially in the context of infection by mutant strains, authorities said. The recommendation for the Bharat Biotech vaccine came …
Read More »Serum Institute rejects charges made by a participant in a vaccine trial and threatens to claim compensation | India News
NEW DELHI: Primary Vaccine Serum institute India on Sunday rejected allegations that a Covid-19 candidate vaccine has serious side effects and threatened to seek large compensation for “malicious” allegations. A 40-year-old man who took part in the ‘Covidshield’ vaccine trial in Chennai has alleged serious side effects, including virtual neurological …
Read More »Serum Institute to resume Covid-19 vaccine trial after DGCI gives its go-ahead
After pharmaceutical company AstraZeneca announced the resumption of its Covid-19 vaccine trial in the UK, its partner at India Serum Institute said it will also restart trials once the General Medicines Controller of India (DGCI) gives its okay. The DGCI previously sent a show of cause notice to the Pune-based …
Read More »